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Summary
Objective: The natural repair of osteochondral defects can be enhanced with biocompatible, biodegradable materials that support the repair
process. It is our hypothesis that hyaluronan-based scaffolds are superior to synthetic scaffolds because they provide biological cues.We tested
this thesis by comparing two hyaluronan-based scaffolds [auto cross-linked polysaccharide polymer (ACP) and HYAFF-11] to polyester-
based scaffolds [poly(DL-lactic-co-glycolic acid) (PLGA) and poly(L-lactic acid) (PLLA)] with similar pore size, porosity and degradation times.
Design: Fifty-four rabbits received bilateral osteochondral defects. One defect received a hyaluronan-based scaffold and the contralateral
defect received the corresponding polyester-based scaffold. Rabbits were euthanized 4, 12 and 20 weeks after surgery and the condyles
dissected and processed for histology.
Results: Only ACP-treated defects presented bone at the base of the defect at 4 weeks. At 12 weeks, only defects treated with rapidly
dissolving implants (ACP and PLGA) presented bone reconstitution consistently, while bonewas present in only one third of those treated with
slowly dissolving scaffolds (HYAFF-11 and PLLA). After 20 weeks, the articular surface of PLGA-treated defects presented ﬁbrillation more
frequently than in ACP-treated defects. The surface of defects treated with slowly dissolving scaffolds presented more cracks and ﬁssures.
Conclusions: The degradation rate of the scaffolds is critical for the repair process. Slowly dissolving scaffolds sustain thicker cartilage at the
surface but, it frequently presents cracks and discontinuities. These scaffolds also delay bone formation at the base of the defects.
Hyaluronan-based scaffolds appear to allow faster cell inﬁltration leading to faster tissue formation. The degradation of ACP leads to rapid
bone formation while the slow degradation of HYAFF-11 prolongs the presence of cartilage and delays endochondral bone formation.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.





It is well known that articular cartilage is an avascular tissue
and, as such, it lacks access to progenitor cells1e3. This is
one of the reasons why the intrinsic repair capacity of
articular cartilage is very limited4e8. Some studies indicate
that lesions which penetrate the subchondral bone are
capable of repair in young animals, while defects in older
animals, either partial thickness (penetrating the cartilage
alone) or full thickness (with access to the subchondral
bone) are generally incapable of successful natural repair9.
Many researchers have addressed this inadequate intrinsic
repair capacity of articular cartilage by attempting to provide
the repair site with either exogenous cells10e32 or cytoki-
nes33e37 in a variety of delivery vehicles22,27,38e48. Even
though early hyaline cartilage tissue repair has been
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tent, long-term regeneration of articular cartilage in an adult
animal has not yet been achieved8,27,49e51.
In the past, our laboratory has used chondrocytes30,31,52,
bone marrow53 and bone marrow-derived mesenchymal
stem cells16,17,52,54 combined with biocompatible delivery
systems for repairing osteochondral defects. Previous
results with a type I collagen gel used as a delivery vehicle
for these cells showed limited repair with incomplete
integration of the neo-cartilage with the surrounding articular
cartilage. Deterioration of the repair site was observed within
a few months following surgery29e31.
We have, more recently, focused on the application of
novel hyaluronan-based scaffolds that support osteogenic
and chondrogenic differentiation of bone marrow-derived
mesenchymal stem cells and their application to the repair of
osteochondral defects26,46,52,55e57. In these experiments,
defects treated with hyaluronan-based scaffolds presented
better short- (4 weeks) and medium-term (12 weeks)
outcomes than untreated defects. Hyaluronan-based poly-
mers have the potential to not only provide a supporting
scaffold for the cells early in the repair process, but may also
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cess57,58 carried out primarily by mesenchymal stem cells
presumably originating from the underlying bone marrow3.
For example, it has been shown that hyaluronan stimulates
chondrogenesis of embryonic mesenchymal progenitor
cells59,60. With respect to angiogenesis, it has also been
shown that high molecular weight hyaluronan inhibits
angiogenesis61e63, while it has been reported that low
molecular weight hyaluronan stimulates it64,65. Lastly,
hyaluronan is a major component of the embryonic
mesenchyme61 and it appears to play a signiﬁcant role in
chondrogenic condensation and the assembly of the
extracellular matrix of the cartilage anlage during limb
formation. The use of hyaluronan in cartilage tissue
engineering scaffolds may establish an embryonic-like
microenvironment to support the reparative events.
The present study was designed to test the hypothesis
that hyaluronan-based scaffolds are superior to other
scaffolds because they provide not only structural but also
biological support to the reparative process. We have tested
this thesis by comparing hyaluronan-based scaffolds to
synthetic polyester-based scaffolds manufactured to match
the physical characteristics (pore size, porosity and
degradation time) of the hyaluronan-based scaffolds.
Methods
HYALURONAN-BASED SCAFFOLDS
Two hyaluronan-based polymers were used in this study;
both polymers were provided by Fidia Advanced Biopoly-
mers srl (Abano Terme, Italy). ACP (auto cross-linked
polysaccharide polymer) is a cross-linked derivative of
hyaluronan that is generated by condensation and, as such,
has no residues different from hyaluronan66. The stability of
the polymer is achieved by directly esterifying some of the
carboxylic groups of glucuronic acid along the chain with
hydroxyl groups of the same or different hyaluronan
molecules. HYAFF-11 sponges are made of a linear
derivative of hyaluronan modiﬁed by complete esteriﬁcation
of the carboxylic function of the glucuronic acid with benzyl
groups66.
PLLA AND (PLGA) SCAFFOLD FABRICATION
Two polyester-based polymers were used in this study:
poly(DL-lactic-co-glycolic acid) (PLGA) and poly(L-lactic
acid) (PLLA). Scaffolds from these materials were prepared
using a solvent casting/particulate leaching method pre-
viously described67. For the PLGA (Polysciences, Warring-
ton, PA, USA) foams, 0.9 g of PLGA 50/50 with 38,500
number average molecular weight (Mn) and 78,300 weight
average molecular weight (Mw) dissolved in 10 mL of
methylene chloride (Acros, Pittsburgh, PA, USA) and
5.1 g of NaCl (Fisher, Pittsburgh, PA, USA), sieved to
150e300 mm, were placed in a teﬂon-lined petri dish
(60 mm diameter). The solvent was allowed to evaporate
for 2 days, resulting in a composite material approximately
85% salt by weight. The casting was broken into small
pieces and placed in a stainless steel mold with a teﬂon
insert (12.7 mm inner diameter, 50 mm long). The mold was
heated with a band heater (Watlow, St. Louis, MO, USA).
After increasing the temperature from 25(C to 100(C at
a rate ofw25(C/min, the mold was compressed at 1.4 MPa
with a hydraulic press (Model 3912, Carver, Warsaw, IN,
USA) for 20 min at a constant temperature (100(C).For the PLLA foams, 0.6 g of PLLA (Polysciences) with
50,600 Mn and 86,200 Mw dissolved in 10 mL of methylene
chloride (Fisher) and 5.4 g of NaCl (Acros), sieved to
150e300 mm, were placed in a teﬂon-lined petri dish
(60 mm diameter). The solvent was allowed to evaporate
for 2 days, resulting in a composite material approximately
90% salt by weight. The casting was broken into small
pieces and placed in a stainless steel mold (12.1 mm inner
diameter, 50 mm long). The mold was heated with a band
heater (Watlow). After increasing the temperature from 25(C
to 185(C at a rate ofw25(C/min, the mold was compressed
at 1.4 MPa with a hydraulic press (Model 3912, Carver) for
20 min at a constant temperature (185(C).
After cooling, the PLGA or PLLA/salt cylinders were
removed from the mold and cut with a diamond saw (Model
650, South Bay Technologies, San Clemente, CA, USA)
into discs with a thickness of 3 mm. Up to ﬁve discs were
then placed in 250 mL of distilled water for 2 days to remove
the salt. Leached foams were then vacuum dried overnight
at 1.33 Pa and stored dry until sterilization. Sterilization was
completed by exposing the scaffolds to ethylene oxide gas
(Anprolene Sterilizer, Anderson Products, Haw River, NC,
USA) for 12 h.
SCAFFOLD CHARACTERIZATION
Gel permeation chromatography (GPC)
Molecular weight of polymers received from Polysciences
was determined in triplicate via a GPC equipped with
a differential refractometer (Model 410, Waters, Milford,
PA). A linear Phenogel column (5 mm, mixed bed, Phenom-
enex, Torrance, CA, USA) was used for these measure-
ments and the GPC was operated at a ﬂow rate of 1 mL/min.
Molecular weights were determined from elution time
based on a calibration curve generated with polystyrene
standards (Polysciences). For both PLGA and PLLA,
the MarkeHouwink constants for PLLA were used:
KZ 5.45! 103 mL/g and aZ 0.7368.
Mercury intrusion porosimetry
The porosity, total surface area, and pore size distribu-
tion of the dried scaffolds were characterized with
mercury intrusion porosimetry (Autoscan-500, Quantach-
rome, Boynton Beach, FL, USA). One sample of each of
the scaffolds of approximately 0.02e0.04 g was tested.
Pressure was ramped from 4.8 to 344.7 kPa for each
measurement. Equations used to determine porosity and
pore size distribution in similar scaffolds have been
described previously67,69. The advancing contact angle
between mercury and PLGA 50:50 is 135( and between
mercury and PLLA is 160(69. The polymer densities are
1.35 g/cm3 for PLGA 50/50 and 1.26 g/cm3 for PLLA69.
The surface tension of mercury is 480 dyn/cm67. In the
absence of any available data, the contact angle between
mercury and hyaluronic acid was taken to be the same as
for PLGA to facilitate comparison between the scaffolds.
Thus, while measurements of percent porosity are
accurate, data pertaining to pore size and pore size range
should be considered relative values for ACP and
HYAFF-11 samples68,69.
Mechanical test
Stiffness of hydrated, empty scaffolds was determined. A
cartilage indenter70e73 was modiﬁed to measure the
mechanical properties of the samples in unconﬁned
compression under constant load, i.e., in creep mode74,75.
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platen. All tests were performed with the sample immersed
in physiological saline. A tare load was ﬁrst applied to ensure
good contact between loading platens and the sample.
When the sample displacement reached equilibrium, a test
load sequence consisting of ﬁve load increments of 0.5 g
was applied. Each increment was held constant until the
displacement reached equilibrium. Equilibrium stress and
strain were determined for each load increment. Young’s
modulus of the sample was then determined from the slope
of equilibrium stress/strain. Three 7-mm diameter by 3-mm
thick replicate samples were tested for each scaffold. A
good ﬁt to a straight-line model was found.
Scanning electron microscopy (SEM)
A series of SEM samples of the scaffolds were prepared.
The samples were ﬁxed in 0.5% glutaraldehyde in
phosphate-buffered saline (PBS, pH 7.4) overnight at
4(C, washed in 0.2 M sodium cacodylate three times, and
postﬁxed in 1% osmium tetroxide in 0.1 M sodium
cacodylate for 30 min at 4(C. The composites were washed
once with water, dehydrated in a graded series of alcohols
and critical point dried in a critical point dryer (CPD020,
Balzers Union, Principality of Liechtenstein). The compo-
sites were glued onto SEM stubs with silver paint, lightly
coated with platinum/gold in an ion coater (IB3, RMC Eiko
Corp., Tucson. AZ, USA), and observed in a JSM 840A
scanning electron microscope (Jeol Ltd., Tokyo, Japan).
PREPARATION OF THE IMPLANTS
Pre-wetting
Prior to ﬁbronectin coating, the PLLA and PLGA scaffolds
were pre-wet by immersion in absolute ethanol in a 5-mL
tube76. The tube was then capped, and negative pressure
was applied to the tube with a 20-mL syringe ﬁtted with
a 20-gauge needle; this vacuum facilitated the exit of air
bubbles and allowed complete inﬁltration of the delivery
vehicles with the ethanol. The implants were then removed
from the ethanol and placed in sterile buffered saline
solution for 30 min at room temperature. This 30-min wash
was repeated three times and, after the third change, the
scaffolds were incubated in sterile buffered saline overnight
at room temperature.
Fibronectin coating
All four implant materials were cut into 3-mm diameter
cylinders with a biopsy punch (Premier Medical Products,
King of Prussia, PA, USA) and then pre-coated by
immersion into a 100 mg/mL solution of ﬁbronectin77
(Collaborative Biomedical Products; Collaborative Re-
search Inc., Bedford, MA, USA) in Tyrode’s salt solution
in a 5-mL tube. The tube was then capped, and negative
pressure was applied to the tube with a 20-mL syringe ﬁtted
with a 20-gauge needle; this vacuum facilitated the exit of
air bubbles and allowed complete inﬁltration of the delivery
vehicles with the ﬁbronectin solution. After a 1-h incubation
at 4(C, the implants were removed from the ﬁbronectin
solution and dried overnight at room temperature.
SURGICAL PROCEDURE
A total of 54, 4-month-old New Zealand White rabbits
(Hazelton Research Inc., Denver, PA, USA) weighing2.6e3.0 kg were used in this study. All procedures followed
an Institutional Animal Care and Use Committee-approved
protocol.
Rabbits were anesthetized by intramuscular injection of
a mixture of ketamine hydrochloride (100 mg/mL,
0.60e0.70 mL/kg of body weight; Aveco, Fort Dodge, IA,
USA) and xylazine (20 mg/mL, 0.30 mL/kg of body weight;
Rugby Laboratory, Rockville Centre, NY, USA). The knee
joint was exposed through an incision from the medial edge
of the patella to the anterior edge of the distal insertion of
the medial collateral ligament. Any bleeding was carefully
controlled. The capsule was incised and the medial femoral
condyle exposed after lateral dislocation of the patella and
resection of the intrapatellar fat tissue. With the knee
maximally ﬂexed, a hand-driven drill was used to create
a full-thickness defect (3-mm in diameter! 1.5-mm deep)
through the articular cartilage and into the subchondral
bone on the center of the medial femoral condyle, 1.5 mm
above the edge of the medial meniscus. All debris was
removed from the defect with a curette, and the edges were
cleaned with a scalpel blade. The implants were then press-
ﬁt into the defect and, after reducing the patella, the capsule
and muscle were closed with double 4-0 dexon suture and
the skin with a continuous 4-0 dexon suture.
Each rabbit received a hyaluronan-based sponge in one
knee and corresponding polyester-based sponge in the
contralateral knee. This design allows the comparison of
matched pairs of defects. The intrinsic variability of surgical
animal models, particularly that of the rabbits, necessitates
this paired comparison.
MACROSCOPIC EXAMINATION
Rabbits were euthanized at 4, 12 and 20 weeks after
surgery by intravenous overdose of sodium pentobarbital.
The knee joint was approached as described above and the
distal femoral condyles dissected. The gross appearance of
the defects was assessed as described previously29,30,55,
taking into consideration the surface characteristics of the
repair and its continuity with the host tissue as well as the
presence of osteoarthritic changes throughout the joint.
HISTOLOGIC PROCESSING
After macroscopic examination of the knees, the speci-
mens were ﬁxed in 10% buffered formalin, demineralized
with RDO (Rapid Bone Decalciﬁer, Apex Engineering,
Plainﬁeld, IL, USA) and embedded in parafﬁn. Sections of
6-mm were cut through the entire thickness of the defect.
Adjacent sections were stained with Toluidine blue or
immunostained with antibodies against type II collagen
(Developmental Studies Hybridoma Bank, Cat# II-II6B3).
For immunohistochemistry, deparafﬁnized sections were
digested with pronase for 15 min and then blocked with 5%
bovine serum albumin (BSA) in PBS for 30 min. Primary
antibody or control IgG were applied in 1% BSA in PBS for
1 h. Secondary antibody was ﬂuorescein isothiocyanate-
conjugated goat anti-Mouse IgG (Chemicon, Temecula,
CA). Wet mounts were immediately documented with
a 20! objective, using a ﬂuorescence microscope and
a SPOT-RT digital camera.
Sections through the center of the defects were used for
histomorphometric measurements. The defect area was
divided into two compartments; the area comprised
between the idealized cartilage surface and tidemark that
should therefore be ﬁlled by cartilage and the area between
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ﬁlled by bone and bone marrow/interstitial space. The areas
occupied by cartilage, bone, bone marrow/interstitial space
and ﬁbrocartilaginous tissue were measured within these
two compartments using Image Pro Plus (Media Cybernet-
ics, Inc., Silver Spring, MD, USA) and expressed as
a percentage of the total area of the compartment being
analyzed. The different tissue types were identiﬁed manu-
ally by the operator since the toluidine blue staining did not
provide sufﬁcient contrast for a fully automated selection. All
histomorphometric measurements were performed blindly
by two independent operators; the operators did not know
the treatment group or follow-up time of the specimens
being analyzed.
STATISTICAL ANALYSIS
The statistical signiﬁcance of the differences in the
histomorphometric measurements was determined by re-
peated measurements analysis of variance in conjunction
with Tukey’s post hoc test, using Statistica (StatSoft, Tulsa,




ACP sponges of the lot # 109/97 have an average pore
size of 26 mm, a porosity of 85%, a surface area of
0.1308 m2/cm3 and a Young’s modulus of 8.2 kPa while
those from lot # 014/00 have an average pore size of
29 mm, a porosity of 86%, a surface area of 0.1031 m2/cm3
and a Young’s modulus of 7.6 kPa (Fig. 1, Table I).
HYAFF-11 sponges have an average pore size of
83 mm, a porosity of 80%, a surface area of 0.0387 m2/
cm3 and a Young’s modulus of 42.1 kPa (Fig. 1, Table I).
PLGA 50/50 has an average pore size of 28 mm, a porosity
of 82%, and a surface area of 0.1228 m2/cm3 and a Young’s
modulus of 11.6 kPa (Fig. 1, Table I). PLLA foams have an
average pore size of 92 mm, a porosity of 87% and a surface
area of 0.0371 m2/cm3 and a Young’s modulus of 40.6 kPa
(Fig. 1, Table I).MACROSCOPIC FINDINGS
The macroscopic appearance of the study groups was
very similar at every time point. Four weeks after surgery,
the defects were 80e90% ﬁlled with a translucent tissue; the
central area of the defect was slightly depressed and the
edges were clearly recognizable. No signs of signiﬁcant
osteoarthritis were present in any of the specimens. After 12
weeks, small osteophytes were present in one of the ACP-
treated defects, in two of the PLGA-treated defects, in two of
the HYAFF-11-treated defects and in two of the PLLA-
treated defects. Two of the ACP-treated defects, four of
the PLGA-treated defects, three of the HYAFF-11-treated
defects and three of the PLLA-treated defects demonstrated
osteophytes 20 weeks after surgery.
HISTOLOGIC FINDINGS
ACP
At the 4-week time point, six of the nine defects treated
with ACP sponges exhibited similar repair to that reported
previously with this scaffold26,46 (Fig. 2). Brieﬂy, no
remnants of the scaffold are visible and the reparative
tissue ﬁlling the defects appeared slightly depressed in the
center of the defect with respect to the level of the adjacent
cartilage. The superﬁcial layer of the repair was composed
of hyaline-like cartilage well integrated with the adjacent
host cartilage. The basal zone of the defect presented
endochondral bone formation with different levels of
maturation in different specimens, reﬂecting typical inter-
individual variation. The last three specimens received
a different batch of ACP (lot # 014/00) sponge and
exhibited substantially different results at this time point,
with cartilage formation at the periphery of the repair area,
but only undifferentiated tissue in the center and no bone
formation; also, the depression in the center of the repair
was more prominent. These results are very similar to those
previously observed in 3-week specimens treated with
ACP sponges26.
At the 12-week harvest time, the defects treated with
ACP sponges exhibited similar repair to that reported
previously with this scaffold at this time point26,46 (Fig. 3).
Brieﬂy, the defects were ﬁlled with bone up to and slightly
beyond the level of the tidemark. The superﬁcial layer wasFig. 1. SEM of the scaffolds.
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ACP (lot # 109/97) 26 6e278 85 0.1308 8.2
ACP (lot # 014/00) 29 4e358 86 0.1031 7.6
PLGA 50/50 28 4e504 82 0.1228 11.6
HYAFF 83 4e345 80 0.0387 42.1
PLLA 92 6e545 87 0.0371 40.6composed primarily of hyaline-like cartilage and, in approx-
imately half of the specimens, protruded beyond the level of
the adjacent cartilage.
Twenty weeks after implantation, defects that received
ACP sponges presented very similar results to those
described for the 12-week follow-up (Fig. 4). The defects
were ﬁlled with bone slightly beyond the level of the
tidemark and the superﬁcial layer was composed primarily
of cartilage showing signs of mild ﬁbrillation in only two out
of eight specimens.
PLGA
Four weeks after surgery, the defects treated with PLGA
sponges presented similar results in all nine specimens
(Fig. 2). The scaffold was dissolved as in the case of ACP-
treated defects and the reparative tissue formed a network
that did not completely ﬁll the defect area. The majority of
the tissue in this ‘‘network’’ appeared to be hyaline-like
cartilage. In contrast to the ACP-treated defects, no bone
formation was evident in any of the PLGA-treated defects.
Only two of the nine defects presented a thick superﬁcial
layer of cartilaginous tissue. The integration of the re-
parative tissue with the adjacent tissue was inferior to that
observed in ACP-treated defects.
Twelve weeks after surgery, the defects treated with
PLGA sponges presented similar results in all specimens
(Fig. 3) with bone ﬁlling the defect up to and slightly beyond
the level of the tidemark, except in one of the specimens
that exhibited an area of hypertrophic cartilage in the center
of the defect. The superﬁcial layers of the defect appear to
be formed of hyaline-like cartilage and, overall, present
good integration with the adjacent tissue. However, this
cartilaginous layer is thinner than that formed in defects
treated with ACP sponges and about half as thick as
normal cartilage.
At the 20-week time point, PLGA-treated defects pre-
sented bone ﬁlling the defect slightly beyond the level of the
tidemark with a superﬁcial layer presenting hyaline-like
cartilage (Fig. 4). This superﬁcial layer presented signs of
ﬁbrillation in ﬁve out of the eight defects.
HYAFF-11
At the 4-week time point, the defects treated with
HYAFF-11 sponges exhibited similar repair to that
reported previously with this scaffold at this time point46
(Fig. 2). Brieﬂy, the scaffold is still present and the pores
within the sponge were ﬁlled with hyaline-like and hyper-
trophic cartilage. In half of the specimens, ﬁbrous or
ﬁbrocartilaginous tissue occupied the uppermost layer of
the repair tissue. In the majority of the defects, the repair
tissue presented good integration with the adjacent
cartilage. The central areas of the scaffold had not been
inﬁltrated with cells as effectively as those in the peripheryand surface of the defect, or some of the cells that initially
inﬁltrated the area had expired due to nutrient insufﬁciency.
Twelve weeks after surgery, all the HYAFF-11-treated
defects presented similar appearance (Fig. 3). Remnants of
the scaffold were identiﬁable in the deeper areas of the
defect which was ﬁlled, almost in its entirety, with cartilage.
Peripheral areas of this cartilage mass appeared hypertro-
phic, but only half of the defects presented some bone
formation. In the majority of the specimens, the cartilaginous
mass appeared detached from the rest of the tissue. This
could be an artifact of the histologic processing, but also
may indicate a weakened area within the repair tissue. Signs
of mild ﬁbrillation were visible in the superﬁcial layers of two-
thirds of the specimens, as has been noted previously.
At the 20-week harvest time, defects that received
HYAFF-11 sponges presented no evidence of residual
scaffold; large amounts of cartilage ﬁlled the defect (Fig. 4).
Only two of the eight defects presented satisfactory bone
ﬁlling and good integration of the cartilaginous layer. The
endochondral bone replacement of the cartilaginous tissue
ﬁlling the defect appeared to be delayed in the remaining six
specimens. This delayed bone formation coincided with
poor integration of the repair tissue and numerous ﬁssures
and cracks within the cartilaginous mass ﬁlling the defects,
probably due to slower degradation of the scaffold.
PLLA
Four weeks after surgery, the defects treated with PLLA
sponges presented similar results in all nine specimens
and, to some degree, similar to those obtained with PLGA
sponges (Fig. 2) except for the presence of the scaffold
within the defects; although the scaffold does not stain with
toluidine blue, it is visible within the repair tissue. The
reparative tissue formed a network that did not completely
ﬁll the defect area. The majority of the tissue in this
‘‘network’’ appeared to be hyaline-like cartilage. No bone
formation was evident in any of the PLLA-treated defects.
The three-dimensional structure of the PLLA sponges
appeared to be more rigid than that of HYAFF-11
sponges, producing a more homogeneous appearance of
the tissue within the defect. However, the cellular inﬁltration
of the scaffold appeared to be slightly lower than that in the
case of HYAFF-11 sponges.
At the 12-week harvest time, the defects treated with
PLLA sponges still presented some residual scaffold within
the repair tissue. The repair presented a superﬁcial layer of
hyaline-like cartilage that varied in thickness and integrity
among the specimens (Fig. 3). In approximately half of the
specimens, this cartilaginous layer was as thick as the
adjacent cartilage and presented good structural integrity
with no cracks or ﬁssures. In most of the specimens, the
integration of the repair tissue with the host cartilage was
superior in the anterior edge. At the base of the defect, bone
with relatively normal morphology was present in only three
Fig. 2. Light microscopy of the osteochondral defects 4 weeks after implantation. Panels in the left column depict toluidine blue-stained
specimens of each treatment group (20!); panels in the right column display the areas within the boxes stained with antibodies against type II
collagen (75!).
Fig. 3. Light microscopy of the osteochondral defects 12 weeks after implantation. Panels in the left column depict toluidine blue-stained
specimens of each treatment group (20!); panels in the right column display the areas within the boxes stained with antibodies against type II
collagen (75!).
Fig. 4. Light microscopy of the osteochondral defects 20 weeks after implantation. Panels in the left column depict toluidine blue-stained
specimens of each treatment group (20!); panels in the right column display the areas within the boxes stained with antibodies against type II
collagen (75!).
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or calciﬁed cartilage ﬁlled the pores of the scaffold that was
still present at this harvest time.
Twenty weeks after surgery, PLLA-treated defects
presented suboptimal bone ﬁlling of the defect area
(Fig. 4). In some of the specimens, the scaffold was still
visible at this time point. The surface of the defect was
ﬁbrillated in four specimens that presented a thicker
cartilaginous layer, while in the remaining four defects this
cartilaginous layer was very thin and presented cracks and
discontinuities.
HISTOMORPHOMETRIC MEASUREMENTS
The results of the histomorphometric analysis of the
repair are presented in Fig. 5; the means of the measure-
ments for each tissue type in the two compartments
(chondral and bony) are displayed as pie charts for each
material and follow-up time. The statistical analysis of these
Fig. 5. Histomorphometric analysis. Pie charts representing the
relative amounts of different tissues found within the cartilaginous
(A) and bony (B) compartments of the defect for each scaffold and
time point. The means for each treatment group and time point are
displayed here.measurements revealed differences (P! 0.05) in the
relative amounts of different tissues (Fig. 5). We highlight
some of these differences in the paragraphs below.
In the chondral compartment [Fig. 5(A)], HYAFF-treated
defects presented more cartilage than defects treated with
either PLGA or PLLA 4 weeks after surgery and more
cartilage than any other treatment group 20 weeks after
surgery. Defects treated with fast-dissolving scaffolds
(ACP and PLGA) presented more bone than HYAFF-
treated defects 12 weeks after surgery. After 20 weeks,
ACP-treated defects presented more bone than defects
treated with slow-dissolving scaffolds (HYAFF and PLLA).
In the bony compartment, [Fig. 5(B)], HYAFF-treated
defects presented more cartilage than any other treatment
group at every time point; in addition, defects treated with
slow-dissolving scaffolds presented more cartilage than
defects treated with fast-dissolving scaffolds 12 weeks after
surgery. Defects treated with fast-dissolving scaffolds
(ACP and PLGA) presented more bone than defects
treated with slow-dissolving scaffolds (HYAFF and PLLA)
12 weeks after surgery and more mature bone with better
deﬁned bone marrow than defects treated with HYAFF
both at 12 and 20 weeks after surgery.
Discussion
To test our hypothesis that hyaluronan-based scaffolds
are superior because they provide not only structural but
also biological support to the reparative process, this series
of experiments compares two hyaluronan-based scaffolds
with different degradation times (2 weeks or 2 months) to
polyester-based scaffolds developed to match the physical
characteristics of the hyaluronan-based scaffolds (pore
size, porosity and degradation time).
The residence time of the scaffolds in the defect had
a clear impact in both the timing of the sequence of events
leading to the repair of the surgically created defects and
the ﬁnal outcome of the repair at the longest post-surgical
follow-up time46,56e58.
ACP sponges dissolve in vitro in 2 weeks when placed in
daily changes of PBS at 37(C (unpublished data). HYAFF-
11 sponges dissolve in 10 weeks in vitro in daily changes of
PBS at 37(C (unpublished data). The half-life of PLGA
foams with a similar composition and pore size to those used
in this study wasw3 weeks in vitro andw2 weeks in vivo, as
based on GPC results (molecular weight of polymer)78.
Based onweight, the time required to lose approximately half
of the dry weight wasw12 weeks in vitro78. For PLLA foams
with similar physical characteristics to those used in this
study, the half-life in vitro was w20 weeks, based on GPC
results, and the time to lose approximately half of the dry
weight in vitro wasw40 weeks79.
From observations reported here and elsewhere, we
suggest that the empty scaffolds are ﬂooded with progenitor
cells originating primarily from the underlying bone mar-
row3,9 and that all of these cells form cartilage throughout
the height and width of the defects. Scaffolds that facilitate
or enhance this migration of reparative cells into the defect
area35,36 would be advantageous for the treatment of
osteochondral defects.
The main difference observed between hyaluronan-
based sponges and polyester-based foams is a relative
delay in tissue formation in the defects implanted with
synthetic foams. Because of this, we speculate that one
of the effects of the different chemical composition of
the scaffold is an improvement of initial progenitor cell
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hyaluronan-based scaffolds. This difference may be due
to the chemical composition of the scaffolds either directly
or indirectly, as a result of differences in the surface
chemistry and microarchitecture of the scaffolds and their
ability to retain the ﬁbronectin with which the scaffolds were
coated. This hypothesized increase in the number of repair
cells in the defect early in the repair process would translate
into a better and faster regeneration of the damaged tissue.
However, the observed differences may result from more
than a simple increase in the number of cells that populate
the implant. As mentioned above, hyaluronan is one of the
major components of embryonic extracellular matrix and
it has been hypothesized to play important roles in
development in general and in bone and cartilage differen-
tiation in particular59e62.
Between days 8 and 14, the ACP and PLGA scaffolds
break down extensively. In the case of ACP, this
degradation and the consequent release of biologically
active hyaluronan oligomers early in the repair process may
contribute to or trigger rapid endochondral bone formation at
the base of the defect26,46,55,56,64,65. Hyaluronan oligomers
released upon breakdown of the scaffold induce invasion of
blood vessels63e65 with a resultant inﬂux of osteogenic cells
that fabricate woven bone. We suspect that the overlying
cartilaginous layer is maintained due to the inﬂuence of the
synovial environment and the mechanical stimuli from the
weight-bearing joint.
Since both PLGA and PLLA can be degraded into acidic
by-products80, it is possible that an alteration of local pH
may occur in vivo during the course of implantation, thus
affecting the differentiation of cells recruited into the
scaffolds. While it was not possible to monitor pH in this
study, PLGA scaffolds, with or without seeded muscle-
derived mesenchymal stem cells (MSCs), have been used
previously to regenerate bone and cartilage in rabbit osteo-
chondral defects81. Similarly, both bone and cartilage were
observed in this study at the 12-week and later time points,
suggesting that the degradation products of these scaffolds
do not prevent differentiation of cells at the defect site.
Defects treated with scaffolds with a longer residence
time (HYAFF-11 and PLLA) exhibited a more substantial
delay in bone formation at the base of the defect. Even at
the longer follow-up time, the bone at the base of the defect
was less mature than the bone found in ACP- and PLGA-
treated defects, as indicated by the differences in the
amount of bone marrow and interstitial space present in the
bony compartment of the defects and the subchondral bone
plate and tidemark had not been properly reconstituted. At
the same time, the delayed degradation of the scaffold at
the surface of the defects results in gaps and discontinuities
in the cartilaginous component of the defect. The advanced
maturation stage of the cartilaginous extracellular matrix
does not allow the ﬁlling of the space occupied by the
scaffold that is left unrepaired when the scaffolds dissolve.
It is important to note that, as described in the Results
section, three of the specimens, which received ACP
sponges from a different batch, exhibited substantially
different results at the 4-week time point, with cartilage
formation at the periphery of the repair area, but only
undifferentiated tissue in the center, no bone formation and
a more noticeable depression in the center of the repair.
These results are very similar to those previously observed
in 3-week specimens treated with ACP sponges26. Based
on these observations, we suspect that this particular batch
of ACP sponges dissolves more slowly, which would
explain the apparent delay in the repair process andreinforce the importance of the effects of residence time
of the scaffolds on bone/cartilage formation.
Results also suggest that the local mechanical environ-
ment might play an important role in the chondrogenic
differentiation of cells at the surface of the defect and in
determining the quality of this cartilaginous layer and its
integration with the surrounding host tissue. The rapid
development of bone at the base of the defects with the
faster degrading scaffolds provides a normal or quasi-
normal mechanical environment for the non-calciﬁed
surface layer which results in better integration with the
surrounding cartilage and integrity of the cartilaginous
component of the repair tissue.
Hyaluronan-based scaffolds (ACP and HYAFF-11)
appear to allow faster cell inﬁltration of the defect area,
leading to cartilage and bone formation within the repair
tissue at early time points. Defects treated with PLGA or
PLLA present more interstitial space which, in the early time
points, primarily represents unﬁlled voids within the defect.
It is noteworthy that the presence of HYAFF-11 in the
defects appears to correlate with maintenance of cartilage
within the defect and a slow maturation of the bottom of the
defect towards bone formation.
In summary, the degradation rate of the scaffolds is
a critical element of the repair process. The quick
degradation of ACP and PLGA leads to rapid bone
formation, while the slow degradation of HYAFF-11 and
PLLA prolongs the presence of cartilaginous tissue and
delays endochondral bone formation.
In this rabbit model, slow dissolution of the scaffold
sustains thicker cartilage at the surface of the osteochon-
dral repair and appears to delay bone formation at the base
of the defects. This delayed bone formation results in lack of
appropriate mechanical support for the developing over-
lying cartilage which, coupled with the slow dissolution of
the scaffold, might be responsible for the lack of integrity of
the superﬁcial layer of the repair which is observed as
cracks and discontinuities.
We speculate that, although the rapid dissolution of ACP
and PLGA appears to be suitable in this rabbit model,
a different, more clinically-relevant model would exhibit
a slower repair sequence and, thus, might necessitate
scaffolds with longer residence time such as HYAFF-11 or
PLLA. This residence time appears to be a key element in
the design of tissue engineering scaffolds and in the
application of particular scaffolds to speciﬁc repair models.
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